scholarly journals An Easy-To-Use Survival Score Compared to Existing Tools for Older Patients with Cerebral Metastases from Colorectal Cancer

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 833
Author(s):  
Dirk Rades ◽  
Trang Nguyen ◽  
Stefan Janssen ◽  
Steven E. Schild

An easy-to-use survival score was developed specifically for older patients with cerebral metastases from colorectal cancer, and was compared to existing tools regarding the accuracy of identifying patients who die in ≤6 months and those who survive for ≥6 months. The new score was built from 57 patients receiving whole-brain irradiation. It included three groups identified from 6-month survival rates based on two independent predictors (performance status and absence/presence of non-cerebral metastases), with 6-month survival rates of 0% (0 points), 26% (1 point), and 75% (2 points), respectively. This score was compared to diagnosis-specific scores, namely the diagnosis-specific graded prognostic assessment (DS-GPA), the Dziggel-Score and the WBRT-30-CRC (whole-brain radiotherapy with 30 Gy in 10 fractions for cerebral metastases from colorectal cancer) score and to a non-diagnosis-specific score for older persons (Evers-Score). Positive predictive values were 100% (new score), 87% (DS-GPA), 86% (Dziggel-Score), 91% (WBRT-30-CRC), and 100% (Evers-Score), respectively, for patients dying ≤6 months, and 75%, 33%, 75%, 60%, and 45%, respectively, for survivors ≥6 months. Of the five tools, the new score and the Evers-Score were most precise in identifying patients dying ≤6 months. The new score and the Dziggel-Scores were best at identifying patients surviving ≥6 months. When combining the results, the new score appeared preferable to the existing tools. The score appears not necessary for patients with additional liver metastases, since their 6-month survival rate was 0%.

1998 ◽  
Vol 5 (2) ◽  
pp. 124-129 ◽  
Author(s):  
Frederick F. Lang ◽  
David M. Wildrick ◽  
Raymond Sawaya

Background: Metastatic brain tumors represent the most common neurological complication in patients with systemic cancer. They are predominantly cerebrally located and constitute a significant source of morbidity and mortality. The overall incidence of brain metastases exceeds that of all other intracranial tumors, and as improved systemic cancer treatments have extended patients’ lives, this number is rising. Methods: The role of surgery in the management of cerebral metastases is reviewed by considering patient selection criteria, surgical approaches to metastases, intraoperative adjuncts, whole-brain irradiation as a postoperative adjuvant, resection of multiple vs single metastases, and the relative roles of stereotactic radiosurgery and conventional surgery. Results: Surgical resection of single or multiple metastases can be effective management for patients with otherwise good prognoses, providing all the known metastases can be removed without producing significant neurologic deficit. Radiosurgery, an alternate approach, can be used for smaller or inaccessible tumors. Conclusions: The presence of multiple brain metastases does not automatically contraindicate surgery because in properly selected patients, resection of multiple metastases can extend survival and enhance the quality of life. An awareness of how the modalities of open craniotomy, whole-brain radiotherapy, and stereotactic radiosurgery best complement each other will result in the best outcomes.


Author(s):  
Dianne Hartgerink ◽  
Anna Bruynzeel ◽  
Danielle Eekers ◽  
Ans Swinnen ◽  
Coen Hurkmans ◽  
...  

Abstract Background The clinical value of whole brain radiotherapy (WBRT) for brain metastases (BM) is a matter of debate due to the significant side effects involved. Stereotactic radiosurgery (SRS) is an attractive alternative treatment option that may avoid these side effects and improve local tumor control. We initiated a randomized trial (NCT02353000) to investigate whether quality of life is better preserved after SRS compared with WBRT in patients with multiple brain metastases. Methods Patients with 4 to 10 BM were randomized between the standard arm WBRT (total dose 20 Gy in 5 fractions) or SRS (single fraction or 3 fractions). The primary endpoint was the difference in quality of life (QOL) at three months post-treatment. Results The study was prematurely closed due to poor accrual. A total of 29 patients (13%) were randomized, of which 15 patients have been treated with SRS and 14 patients with WBRT. The median number of lesions were 6 (range, 4-9) and the median total treatment volume was 13.0 cc 3 (range, 1.8-25.9 cc 3). QOL at three months decreased in the SRS group by 0.1 (SD=0.2), compared to 0.2 (SD=0.2) in the WBRT group (p=0.23). The actuarial one-year survival rates were 57% (SRS) and 31% (WBRT) (p=0.52). The actuarial one-year brain salvage-free survival rates were 50% (SRS) and 78% (WBRT) (p=0.22). Conclusion In patients with 4 to 10 BM, SRS alone resulted in one-year survival for 57% of patients while maintaining quality of life. Due to the premature closure of the trial, no statistically significant differences could be determined.


2012 ◽  
Vol 7 (1) ◽  
Author(s):  
Henrik Hauswald ◽  
Jan-Oliver Dittmar ◽  
Daniel Habermehl ◽  
Stefan Rieken ◽  
Florian Sterzing ◽  
...  

2005 ◽  
Vol 71 (3) ◽  
pp. 281-286 ◽  
Author(s):  
Barbara-Ann M. Millar ◽  
Thomas G. Purdie ◽  
Ivan Yeung ◽  
Gregory R. Pond ◽  
Susan Billingsley ◽  
...  

2010 ◽  
Vol 49 (3) ◽  
pp. 382-388 ◽  
Author(s):  
Katarzyna Komosinska ◽  
Lucyna Kepka ◽  
Anna Niwinska ◽  
Lucyna Pietrzak ◽  
Marek Wierzchowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document